Recent Material Events - Genemax Corp (GMXX)

Filing Date	Description
2008-05-15	PART 2 — RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) ...
2008-04-14	Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X] ...
2007-12-06	In further reference to the Company’s previous Form 8-K dated October 25, 2007, the Company received notice on November 28, 2007, from the U.S. Patent and Trademark Office that its petition to revive U.S. Patent Appln. No. 10/046,542 has bee ...
2007-11-15	The following unaudited consolidated interim financial statements of TapImmune Inc. are included in this Quarterly Report on Form 10-QSB: ...
2007-10-26	In respect of the United States patent situation on the technology of TapImmune Inc. (the “Company”) for treatments using “TAP” gene enhancement, the Company has an issued patent, U.S. 6,361,770, issued March 26, 2002, covering au ...
2006-02-03	On January 24, 2006, the Board of Directors of GeneMax Corp. (the " Company " ) confirms that, in accordance with the terms and conditions of a certain " Option and Settlement Agreement " (the " Option and Settlement Agreement " ), dated for referenc... ...
2006-01-03	Effective on December 23, 2005, the Board of Directors of GeneMax Corp. (the "Company") confirms that, in accordance with the terms and conditions of a certain "Letter of Intent" "(LOI"), as entered among each of The University of British Columbia ("... ...
2005-12-09	Effective on December 5, 2005 the Board of Directors (the " Board " ) of GeneMax Corp. (the " Company " ) accepted the resignations of each of Dr. Karl E. Hellstrom and Dr. Terry W. Pearson as directors and officers of the Company (the " Resignations... ...
2005-11-22	GeneMax Corp. is a biotechnology company specializing in the discovery and development of immunotherapeutics for the treatment and eradication of cancer, therapies for infectious diseases and autoimmune disorders and prevention of transplant tissue r... ...
2005-10-12	GeneMax Corp. is a biotechnology company specializing in the discovery and development of immunotherapeutics for the treatment and eradication of cancer, therapies for infectious diseases and autoimmune disorders and prevention of transplant tissue r... ...